This paper describes the results of an open, prospective, non-comparable study of the efficacy and tolerance of the drug phlebodia 600 mg in patients with lower limb CVI. The study accrued 32 patients aged 21-70 years suffering from lower limb varicosity coupled with class I-IV CVI according to the CMP. Of the objective criteria, there were made measurements of the malleolar volume. The grade of subjective symptoms was recorded in terms of the clinical scale for evaluating the severity of the VCSS disease, which is a subdivision of the CEAP classification. The quality of the patients' life was examined before the patient was included into the study and after its completion using a standard CIVIQ questionnaire. The positive time course of changes was marked in all the constituents of the integral indicator of the patient's quality of life. The most significant change in the patients' quality of life was identified in patients in clinical class III according to the CEAP. The authors analyze the reports concerning the use of the above-indicated drug in European phlebological practice.